NextCure (FRA:2US) Short-Term Capital Lease Obligation : €0.00 Mil (As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is NextCure Short-Term Capital Lease Obligation?

NextCure's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2025 was €0.00 Mil.

NextCure's quarterly Short-Term Capital Lease Obligation increased from Sep. 2024 (€0.00 Mil) to Dec. 2024 (€0.76 Mil) but then declined from Dec. 2024 (€0.76 Mil) to Mar. 2025 (€0.00 Mil).

NextCure's annual Short-Term Capital Lease Obligation increased from Dec. 2022 (€0.49 Mil) to Dec. 2023 (€0.60 Mil) and increased from Dec. 2023 (€0.60 Mil) to Dec. 2024 (€0.76 Mil).

NextCure Short-Term Capital Lease Obligation Historical Data

The historical data trend for NextCure's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextCure Short-Term Capital Lease Obligation Chart

NextCure Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.49

0.60

0.76

NextCure Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	-	-	0.76	-

NextCure Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

NextCure Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of NextCure's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

NextCure Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCure Inc (FRA:2US) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

NXTC:USA

Address

9000 Virginia Manor Road, Suite 200, Beltsville, MD, USA, 20705

Website

https://www.nextcure.com

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

NextCure Headlines

No Headlines